Kratak sadr`aj: U periodu od septembra 2007 do fe bruara 2010. ispitana je pojava duboke venske tromboze u kohorti od 79 pacijenata. Prospektivna studija je obuhvatila kontrolnu grupu koja se po odnosu polova i starosti po kla pa sa grupom pacijenata. Analizirano je prisustvo mutacije faktor V G1691A u grupi obolelih i kontrolnoj grupi. Osamnaest obolelih (22,79%; 95% interval poverenja (CI) 13,53% do 32,03%) i ~etiri kontrole (5,63%; 95% CI 0,27-10,99%) bili su nosioci FV Leiden mutacije u heterozigotnom stanju (p = 0,025). Odnos verovatno}a (OR) za nastanak DVT iznosio je 4,94 (95% CI 1,58-15,42) a relativni rizik (RR) 4,04 (95% CI 1,44-11,38) u pore|enju sa nosiocima neizmenjenog gena.^etiri obolela bili su nosioci FV Leiden mutacije u heterozigotnom stanju a nijedna zdrava osoba i stoga su OR i RR ra~unati na osnovu op{te u~estalosti homozigota u beloj populaciji. OR za DVT bio je 47,28 (95% CI 0,04-52167,3) a RR 45,57 (95% CI 0,77; p=0,025) Na{a studija potvr|uje da nosioci FV Leiden mutacije u Vojvodini, kao u studijama ra|enim na drugim populacijama, imaju pove}an rizik za nastanak DVT. Pro cenjen rizik od nastanka DVT za nosioce faktor V Leiden mutacije u heterozigotnom stanju je ~etiri do pet puta ve}i a za homozigotne nosioce ~ak oko 45 do 48 puta ve}i u odnosu na nosioce neizmenjenog gena za FV. Ovi rezultati potvr|uju da kod pacijenata sa DVT, kao i njihovih ro|aka, treba ispitati prisustvo FV Leiden mutacije.Klju~ne re~i: faktor V Leiden, duboka venska tromboza IntroductionInherited thrombophilia represents a variety of gene tically determined abnormalities of haemostatic mecha nisms that are generally associated with incre ased predis po sition to blood coagulation and throm bosis deve lop ment. In a patient with the genetic ano maly linked to venous thrombosis, another inhe rited or acquired risk factor can produce this clinical disorder (1, 2). A case-control study inclu ded 71 healthy controls matched with cases for sex and age. The prevalence of factor V G1691A mutation genotype was analyzed. Eighteen cases (22.79%; 95% confidence interval (CI) 13.53% to 32.03%) and four controls (5.63%; 95% CI 0.27% to 10.99%) were heterozygous carriers of FV Leiden (p= 0.025). The odds ratio for DVT was 4.94 (95% CI 1.58 to 15.42) and the relative risk 4.04 (95% CI 1.44-11.38) compared with FV 1691G carriers. Four cases were homozygous carriers of FV Leiden, giving a prevalence of 5.06% (95% CI 0.23 to 9.89%) and no controls, therefore OR and RR calculation was based on the prevalence of homozygotes in the general Caucasian population. The OR for DVT was 47.28 (95% CI 0.04 -52167.3) and the RR 45.57 (95% CI 0.04 to 49540.77; p=0.025) compared with FV 1691 G carriers. Our study confirms that factor V Leiden carriers in Vojvodina, as in similar studies previously carried out in other populations, have an increased risk of developing DVT. The evaluated risk of DVT in heterozygous carriers of the mutation is four-to five-fold higher, whereas for homozygous carriers it is 45-to 48-fold higher than in non-carriers....
In a 5-year follow-up period 73.3% of the patients used to come regularly to check-ups and among them neither the opiate abuse recurrence nor HCV infection recurrence were registered.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.